Cosentyx® ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
269化膿性無菌性関節炎・壊疽性膿皮症・アクネ症候群1

269. 化膿性無菌性関節炎・壊疽性膿皮症・アクネ症候群


臨床試験数 : 23 薬物数 : 30 - (DrugBank : 12) / 標的遺伝子数 : 15 - 標的パスウェイ数 : 106
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2015-000762-65-DE
(EUCTR)
09/07/201525/06/2015Single-arm study to assess a potential effect of anti-IL-17 (Secukinumab) in the treatment of pyoderma gangrenosuSingle-arm study to assess a potential effect of anti-IL-17 (Secukinumab) in the treatment of pyoderma gangrenosum Pyoderma gangrenosum is an autoinflammatory disease, characterized by relapsing, painful ulcers of the skin. Treatment of PG is difficult. Patients suffer from long hospitalization, pain and reduced life quality. New therapeutic strategies are needed. Immunohistological staining show a high amount of IL-17 in PG. IL-17+ immune cells were located in proximity to cellular damage, indicating an involvement in the pathogenesis. Targeting IL-17 with neutralizing IL-17 antibodies seems promising.
MedDRA version: 20.0;Level: PT;Classification code 10037635;Term: Pyoderma gangrenosum;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Trade Name: Cosentyx®
Product Name: Cosentyx
Product Code: EU/1/14/980/002; EU/1/14/980/003
Technische Universität München, School of Medicine, represented by DeanNULLNot RecruitingFemale: yes
Male: yes
7Phase 2;Phase 3Germany